AstraZeneca is a global company involved in the discovery, early- and late-stage development to manufacturing and distribution, and the global commercialization of primary care, specialty care-led and specialty care medicines.
The company specializes in Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA) along with Infection, Neuroscience and Gastrointestinal (ING) disease areas. The London based company operates in 100+ countries globally. The company recorded sales of USD 23 billion in 2016, a decrease by 5% compared to USD 24.7 billion in 2015. The earnings per share in 2016 was USD 2.77. The fiscal third quarter (Q4) sales were USD 5.6 billion, a decrease of 12% compared to 2015 Q4 sales with earnings per share at USD 1.46. This is due to due to the entry of Crestor (rosuvastatin) as well as Nexium (esomeprazole) generic medicines in the U.S. Sales of Crestor and Nexium in the US declined by 57% and 39%, respectively. Overall U.S. Product Sales declined by 22% in the year to USD 7.4 billion (Q4 2016: lowered by 37% to USD 1.6 billion). Product Sales in Europe declined by 3% in the year to USD 5 billion (Q4 2016: reduced by 3% to USD 1.3 billion).
Strategic highlights: (Q4, 2016)
Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of Rhinocort Aqua (nasal spray) outside the U.S. indicated for allergic and non-allergic rhinitis. (Dec)
Eli Lilly and Company to co-develop MEDI1814, an antibody used for the treatment for Alzheimer’s disease. (Dec)
Allergan plc for the global rights to MEDI2070 (monoclonal antibody) used for treating moderate-to-severe Crohn’s disease. (Oct)
Aralez for beta-blocker medicine Toprol-XL (metoprolol succinate) in the U.S. (Oct)
Received first biologics license application and priority review status with a Prescription Drug User Fee Act (PDUFA) set for the second quarter of 2017 from U.S. FDA for durvalumab to treat bladder cancer. (Dec)
Received review New Drug Application from U.S. FDA for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia. (Oct)
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.